Mr. Allen Davidoff reports

XORTX PROVIDES UPDATE ON ACQUISITION OF RENAL ANTI-FIBROTIC THERAPEUTIC PROGRAM FROM VECTUS BIOSYSTEMS

Further to the press release of Oct. 17, 2025, and an update on Dec. 31, 2025, XORTX Therapeutics Inc. has entered into an extension agreement with Vectus Biosystems Ltd. to allow further time to complete the acquisition of the renal anti-fibrotic therapeutic program from Vectus. The term sheet entered into Oct. 17 to acquire the novel new chemical entity, VB4-P5, along with its associated intellectual property, regulatory documentation and manufacturing data, provided for closing the acquisition no more than 90 days from the execution of the term sheet. The company has entered into an amendment that provides for closing of the acquisition on or before March 31, 2026, to provide additional time for transfer of intellectual property.

The term sheet is subject to finalization of closing documentation, satisfaction of conditions that are typical for a transaction of this type, including receipt of all regulatory approvals, and compliance with applicable stock exchange requirements and applicable securities laws.

In other news, XORTX confirms it has scheduled its annual and special meeting of shareholders for Tuesday, March 24, 2026. Shareholders of record on Feb. 20, 2026, will be entitled to vote at the meeting.

The company also confirms that, in connection with the appointment of Krysta Davies Foss to the board of directors, XORTX has granted, in accordance with the company's stock option plan, 20,000 options to purchase common shares of the company at an exercise price of 69 cents for a period of five years.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: (1) its lead program XRx-026 program for the treatment of gout; (2) the XRx-008 program for ADPKD; and (3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the company is developing XRx-225, a preclinical-stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, it is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

We seek Safe Harbor.